1403-81-2

Usage

Uses

Used in Oncology:
(7R)-8-Ethyl-7,8,9,10-tetrahydro-1,4,6,8α,11-pentahydroxy-7β,10α-bis[[2,3,6-trideoxy-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione is used as an anticancer agent for the treatment of various malignancies, including breast cancer, lung cancer, and leukemia. It functions by interfering with the growth and spread of cancer cells, thereby inhibiting tumor progression and improving patient outcomes.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, (7R)-8-Ethyl-7,8,9,10-tetrahydro-1,4,6,8α,11-pentahydroxy-7β,10α-bis[[2,3,6-trideoxy-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione serves as a key compound in the development of novel anticancer drugs. Its unique structure and activity make it a valuable starting point for the design and synthesis of new therapeutic agents with improved efficacy and reduced side effects.
Used in Clinical Trials:
This anthracycline antibiotic is also utilized in clinical trials to evaluate its safety, efficacy, and optimal dosages for various cancer types. These trials are essential for determining the best treatment protocols and ensuring that the compound is used responsibly and effectively in cancer treatment.
Overall, (7R)-8-Ethyl-7,8,9,10-tetrahydro-1,4,6,8α,11-pentahydroxy-7β,10α-bis[[2,3,6-trideoxy-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione is a promising compound in the fight against cancer, with applications in oncology, pharmaceutical research and development, and clinical trials. Its use is carefully monitored and managed to maximize its potential benefits while minimizing risks to patients.